ArticleFrontiers in oncology2026
Systemic inflammatory biomarkers (NLR, SII, PNI and FPR) combined with CEA for predicting advanced colorectal neoplasms: development and temporal validation of a machine learning model.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic systemic inflammation is closely associated with the initiation and development of colorectal tumors. Biomarkers reflecting inflammatory status may help detect advanced colorectal neoplasms (ACRN), which include advanced adenoma and colorectal cancer. Nevertheless, the diagnostic ability of combined inflammatory and nutritional indicators for ACRN has not been fully clarified. This study evaluated whether several systemic inflammation markers-NLR, SII, PNI, and FPR-together with CEA, can improve the identification of ACRN. Methods: A retrospective analysis was conducted in individuals who received colonoscopy from December 2016 to December 2024. Eligible subjects were randomly assigned to a training set and an internal testing set. Patients enrolled between January 2025 and January 2026 were used as a temporal validation cohort. Correlation analysis together with restricted cubic spline (RCS) modeling was applied to assess the associations between inflammatory markers and ACRN risk. Machine learning approaches were then used to construct prediction models based on NLR, SII, PNI, FPR, and CEA. Model performance was assessed by discrimination ability, calibration, and clinical usefulness. An online calculator was also established to support individualized risk estimation. Results: A total of 1330 individuals were analyzed, including 252(18.95%) cases diagnosed with ACRN. Higher values of NLR, SII, FPR, and CEA were linked to a greater probability of ACRN, while PNI showed a negative relationship. These indicators also displayed clear changes across different stages of disease. Among the evaluated machine learning approaches, the XGBoost model showed the strongest predictive ability. The AUCs reached 0.960 in the training set, 0.944 in the testing set, and 0.908 in the temporal validation cohort. In addition, a web-based calculator was built to support personalized risk assessment. Conclusion: Systemic inflammatory and nutritional biomarkers combined with CEA demonstrated robust predictive performance for identifying advanced colorectal neoplasms and may provide a convenient tool for early risk stratification in colorectal cancer screening.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.